Clinical trial
Study Evaluating MAC-321 in Non-small Cell Lung Cancer Refractory to…
NCT00063219 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00063219 |
|---|---|
| Title | Study Evaluating MAC-321 in Non-small Cell Lung Cancer Refractory to Platinum-based Therapy |
| Official title | A Phase 2, Open-label Study of MAC-321 Administered Intravenously as a Single Agent for the Treatment of Non-small Cell Lung Cancer Refractory to Platinum-based Therapy |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell Lung, Lung Neoplasms |
| Intervention type | Drug |
| Interventions | MAC-321 |
| Enrollment | 48 |
| Primary completion | Feb 1, 2005 |
| Completion | Feb 1, 2005 |
| First posted | Jun 25, 2003 |
| Last update posted | Aug 21, 2009 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: